Or explore alternative tirzepatide delivery methods that may reduce GI side effects
4 A study of two participants cannot establish: The frequency of uncommon adverse events Safety across different ages or health conditions Safety with other medicines or substances Long-term safety Safety through other routes Clinical effectiveness The authors themselves stated that further studies were needed
Curr Pharm Des 20:11261135 Sikiri P, Petek M, Ruman R, Seiwerth S, Grabarevi Z, Rotkvi I, Turkovi B, Jagi V, Mildner B, Duvnjak M, Lang N, Danilovi Z, Cviko A, Kolega M, Sallmani A, Djai S, Bura M, Brki T, Bani M, Dodig M, Cori V, imievi V, Veljaca M, Erceg D, Jeek D, Simuni-Banek L, Skroza N, Buli K, Buljat G, Hanevaki M, Orihova V, Luinger D, Culig J, Separovi J, Marovi A, Mie S, Suchanek E, Matoz W, Perovi D, Gjurain M, Mikulandra S, Dernikovi K, Cuk V, Karakas I (1993) A new gastric juice peptide, BPC
Urinary 8-isoprostane as a biomarker for oxidative stress